Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer

Cancer

Volumn 107, Issue 3, 2006, Pages 530-535

  Michaelson, M Dror ^a   Kaufman, Donald S ^a   Kantoff, Philip ^b   Oh, William K ^b   Smith, Matthew R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Alkaline phosphatase; Bisphosphonates; Bone metastases; N telopeptide; Osteoporosis

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; ATRASENTAN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID;

ADULT; AGED; ARTHRALGIA; ARTICLE; BONE METASTASIS; BONE PAIN; BONE TURNOVER; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRY EYE; DYSPNEA; EDEMA; FATIGUE; FEVER; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART INFARCTION; HUMAN; MALE; MYALGIA; NAUSEA; OSTEOCLAST; OSTEOLYSIS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RHINITIS; UNITED STATES;

AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; DISEASE PROGRESSION; DYSPNEA; EDEMA; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; PYRROLIDINES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33746278493     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22043     Document Type: Article

References (19)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
2. Berruti A, Dogliotti L, Bitossi R, et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol. 2000;164:1248-1253.
3. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005;97:59-69.
4. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458-1468.
5. Ernst DS, Tannock IF, Winquist EW, et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol. 2003;21:3335-3342.
6. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003;21:4277-4284.
7. Casey ML, Byrd W, MacDonald PC. Massive amounts of immunoreactive endothelin in human seminal fluid. J Clin Endocrinol Metab. 1992;74:223-225.
8. Lassiter LK, Carducci MA. Endothelin receptor antagonists in the treatment of prostate cancer. Semin Oncol. 2003;30:678-688.
9. Nelson JB. Endothelin inhibition: novel therapy for prostate cancer. J Urol. 2003;170:S65-67; discussion S67-68.
10. Gohji K, Kitazawa S, Tamada H, Katsuoka Y, Nakajima M. Expression of endothelin receptor a associated with prostate cancer progression. J Urol. 2001;165:1033-1036.
11. Carducci MA, Nelson JB, Bowling MK, et al. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol. 2002;20:2171-2180.
12. Zonnenberg BA, Groenewegen G, Janus TJ, et al. Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer. Clin Cancer Res. 2003;9:2965-2972.
13. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol. 2003;21:679-689.
14. Mohammad K, McKenna C, Mison A, et al. Combined endothelin A receptor antagonist and bisphosphonate treatment more effectively reduces prostate cancer growth in bone than either alone. American Society for Bone and Mineral Research, 27th Annual Meeting. 2005;1213a.
15. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461-3467.
16. Carducci M, Nelson J, Saad F, et al. Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: phase 3 study. ASCO Annual Meeting Proceedings, 2004;22,14S:4508.
17. Lipton A, Sleep DJ, Hulting SM, Isaacson JD, Allen AR. Benefit of atrasentan in men with hormone refractory prostate cancer metastatic to bone. ASCO Annual Meeting Proceedings, 2004;22,14S:4687.
18. Vogelzang NJ, Nelson JB, Schulman CC, et al. Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone-refractory prostate cancer, ASCO Annual Meeting Proceedings, 2005:4563.
19. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655-1664.